Thomas Monath, M.D. To Join KPCB to Advance Innovation in Infectious Diseases with the New KPCB Pandemic and Bio Defense Fund

MENLO PARK, Calif., May 17, 2006 – Kleiner Perkins Caufield & Byers – an innovator in providing “venture and relationship capital” (SM) services to entrepreneurs – is pleased to announce Dr. Thomas P. Monath, M.D. will join the KPCB team as a Partner on June 26, 2006.

Tom Monath said, “I have devoted my career to addressing serious challenges to public health worldwide through scientific breakthroughs and new product development. The opportunity to do this with the resources and network of KPCB provides a broader platform and an ability to work with a variety of exciting young companies across a wide product spectrum.”

Brook Byers of KPCB said, “In February, 2006, we announced the formation of our new $200 Million KPCB Pandemic Preparedness and Biodefense Fund.” Tom’s remarkable career as a senior executive in public health and in vaccine discovery and development will help us accelerate innovation in infectious diseases and pandemic preparedness. He will assist young companies developing novel vaccines, antiviral drugs, rapid diagnostics, and disease surveillance techniques as an active advisor, Board member, and public policy advocate.

Dr. Monath has been Chief Scientific Officer with Acambis and its predecessor companies since 1992. Having previously served as Vice President, Research and Medical Affairs, he was appointed Chief Scientific Officer and a member of the Board in March 2002. During that time, he has overseen the development of many of the products within Acambis’ pipeline of vaccines.

Prior to joining Acambis, he worked as Colonel and Chief of the Virology Division of the US Army Medical Research Institute of Infectious Disease. During almost 20 years as Director of the Centers for Disease Control and Prevention